What are pre-funded warrants in a biotech offering?

A pre-funded warrant is a share that has already been paid for and not yet collected. You paid for the couch; it is sitting in the warehouse; you will send a truck when you feel like it. When a biotech prices an offering "of common stock and pre-funded warrants," some of the buyers are handing over the full share price today, less a fraction of a cent, in exchange for the right to take delivery of the share whenever they choose by paying that fraction.

When Crescent Biopharma priced its offering on 14 July 2026, it sold ordinary shares at $14.50 and pre-funded warrants at $14.499 — a difference of a tenth of a cent, which is exactly the $0.001 exercise price of the warrant. The company received the same money either way. The buyer took the same economic exposure either way.

Why does the word "warrant" mean two different things here?

Both meanings turn up in the same press release, a few lines apart.

The warrant most investors know is a speculative instrument: a right to buy a share at a price set above where the stock trades, good for years, worth nothing unless the stock rises. Those warrants are an overhang. They sit over the share count waiting to be exercised into it.

A pre-funded warrant is close to the opposite. The exercise price is nominal, the money is already in the company's bank account, and there is no scenario where the holder walks away. It is a share wearing paperwork. Mistake one for the other and your share count comes out wrong. Count pre-funded warrants as overhang and you are bracing for dilution that has already happened; count the speculative kind as pre-funded and you have missed dilution that has not.

Why would anyone want the paperwork instead of the share?

For some buyers, owning the share is the problem, because federal law counts a security you can get hold of soon as one you already own. 17 CFR 240.13d-3(d)(1)(i) says a person is the beneficial owner of a security "if that person has the right to acquire beneficial ownership of such security … within sixty days," and it names "the exercise of any option, warrant or right" first on its list. Cross a threshold and public filing obligations follow, along with restrictions that matter a great deal to a fund with a mandate.

The pre-funded warrant is written so that the right never exists. Q32 Bio's July 2026 prospectus supplement is explicit: a holder may not exercise any portion that would push its ownership above 19.99%, or above 4.99% or 9.99% if the purchaser chose one of those lower caps before issuance. The warrant is not exercisable past the cap, so the shares behind it are not acquirable, so they are not counted. That is the entire purpose of the instrument.

So the presence of pre-funded warrants in a deal tells you something specific and fairly mundane: at least one buyer was already a large holder, or intended to become one, and needed to stay under a line. It is more often a sign of a concentrated institutional book than a sign of distress.

What should worry you is the other warrant in the sentence

Edesa Biotech's pricing release of 19 August 2026 puts both instruments in a single paragraph.

The offering was 3,870,500 common shares plus pre-funded warrants for 675,000 more, at $5.50 and $5.4999 respectively, raising roughly $25.0 million. That is the boring half — 4,545,500 shares' worth of stock sold, of which about 15% happens to be in warrant form.

The other half: every share and every pre-funded warrant came with an accompanying common share warrant, exercisable immediately at $7.50. If all of them are exercised, that is another 4,545,500 shares and about $34 million more into the company, at a price above where the deal was struck. Those warrants expire on the earlier of 18 months, or 30 days after Edesa announces Phase 2 topline data for EB06 in vitiligo.

Edesa's new investors are funding the trial and holding a warrant that is worth nothing unless the stock clears $7.50, with a 30-day fuse that lights the morning the data lands. The pre-funded warrants in the same deal do nothing of the kind.

Where do the shares actually show up?

The share count appears in two places and the two do not match.

Shares outstanding on the cover of a quarterly report counts issued shares. A pre-funded warrant has not been exercised, so it is not there. Edesa's 675,000 will be invisible in that line until somebody pays the $0.0001.

Weighted average shares in the earnings-per-share calculation counts them from day one. LB Pharmaceuticals' most recent quarterly filing states the rule plainly: the pre-funded warrants are exercisable at any time for nominal consideration "and are therefore included in basic and diluted weighted average shares outstanding from the date of issuance". The accounting treats them as shares because economically they are.

If you are working out what you own a share of, the EPS denominator is the more honest number. If you are working out market capitalisation from a quoted share count, you are probably undercounting.

The limits of this

Two things a pre-funded warrant is not.

It is not a share. Q32 Bio's prospectus also warns that there is no established public trading market for the pre-funded warrants and that the company does not expect one to develop. A holder who wants to sell has to exercise first. And a holder who is sitting under a 9.99% cap cannot always do that on demand.

It is also not a signal about the company's prospects. The instrument describes a constraint on the buyer, not a view about the drug. Reading enthusiasm or desperation into it is reading something that is not there.

What to watch

• The two exercise prices. A nominal one ($0.001, $0.0001) is a share already sold. A real one above the deal price is future dilution that has not happened yet.
• Whether warrants are "accompanying." A deal where each share comes stapled to a warrant is a structurally different deal from one where they do not, at the same headline dollar figure.
• What the warrant's expiry is tied to. When it is pinned to a data readout, the financing has put a date on the catalyst for you.
• The gap between shares outstanding and the EPS share count. That gap is the pre-funded warrants, and it is disclosed.

This is analysis, not investment advice. Every figure above comes from the company's own pricing release or filing, linked at the point it is used.